Sabrina Paganoni1,2,3, Katharine Nicholson1, James Chan4, Amy Shui4, David Schoenfeld4, Alexander Sherman1, James Berry1, Merit Cudkowicz1, Nazem Atassi1. 1. Department of Neurology, Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge St, Suite 600 Boston, Massachusetts, 02114. 2. Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Boston, Massachusetts. 3. VA Boston Healthcare System, Boston, Massachusetts. 4. Massachusetts General Hospital Biostatistics Center, Boston, Massachusetts.
Abstract
INTRODUCTION: Urate has been identified as a predictor of amyotrophic lateral sclerosis (ALS) survival in some but not all studies. Here we leverage the recent expansion of the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database to study the association between urate levels and ALS survival. METHODS: Pooled data of 1,736 ALS participants from the PRO-ACT database were analyzed. Cox proportional hazards regression models were used to evaluate associations between urate levels at trial entry and survival. RESULTS: After adjustment for potential confounders (i.e., creatinine and body mass index), there was an 11% reduction in risk of reaching a survival endpoint during the study with each 1-mg/dL increase in uric acid levels (adjusted hazard ratio 0.89, 95% confidence interval 0.82-0.97, P < 0.01). DISCUSSION: Our pooled analysis provides further support for urate as a prognostic factor for survival in ALS and confirms the utility of the PRO-ACT database as a powerful resource for ALS epidemiological research. Muscle Nerve 57: 430-434, 2018.
INTRODUCTION:Urate has been identified as a predictor of amyotrophic lateral sclerosis (ALS) survival in some but not all studies. Here we leverage the recent expansion of the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database to study the association between urate levels and ALS survival. METHODS: Pooled data of 1,736 ALSparticipants from the PRO-ACT database were analyzed. Cox proportional hazards regression models were used to evaluate associations between urate levels at trial entry and survival. RESULTS: After adjustment for potential confounders (i.e., creatinine and body mass index), there was an 11% reduction in risk of reaching a survival endpoint during the study with each 1-mg/dL increase in uric acid levels (adjusted hazard ratio 0.89, 95% confidence interval 0.82-0.97, P < 0.01). DISCUSSION: Our pooled analysis provides further support for urate as a prognostic factor for survival in ALS and confirms the utility of the PRO-ACT database as a powerful resource for ALS epidemiological research. Muscle Nerve 57: 430-434, 2018.
Authors: Alberto Ascherio; Peter A LeWitt; Kui Xu; Shirley Eberly; Arthur Watts; Wayne R Matson; Connie Marras; Karl Kieburtz; Alice Rudolph; Mikhail B Bogdanov; Steven R Schwid; Marsha Tennis; Caroline M Tanner; M Flint Beal; Anthony E Lang; David Oakes; Stanley Fahn; Ira Shoulson; Michael A Schwarzschild Journal: Arch Neurol Date: 2009-12
Authors: Petra Kaufmann; John L P Thompson; Gilberto Levy; Richard Buchsbaum; Jeremy Shefner; Lisa S Krivickas; Jonathan Katz; Yvonne Rollins; Richard J Barohn; Carlayne E Jackson; Ezgi Tiryaki; Catherine Lomen-Hoerth; Carmel Armon; Rup Tandan; Stacy A Rudnicki; Kourosh Rezania; Robert Sufit; Alan Pestronk; Steven P Novella; Terry Heiman-Patterson; Edward J Kasarskis; Erik P Pioro; Jacqueline Montes; Rachel Arbing; Darleen Vecchio; Alexandra Barsdorf; Hiroshi Mitsumoto; Bruce Levin Journal: Ann Neurol Date: 2009-08 Impact factor: 10.422
Authors: James Berry; Benjamin Brooks; Angela Genge; Terry Heiman-Patterson; Stanley Appel; Michael Benatar; Robert Bowser; Merit Cudkowicz; Clifton Gooch; Jeremy Shefner; Jurjen Westra; Wendy Agnese; Charlotte Merrill; Sally Nelson; Stephen Apple Journal: Neurol Clin Pract Date: 2021-08
Authors: Kjetil Bjornevik; Zhongli Zhang; Éilis J O'Reilly; James D Berry; Clary B Clish; Amy Deik; Sarah Jeanfavre; Ikuko Kato; Rachel S Kelly; Laurence N Kolonel; Liming Liang; Loic Le Marchand; Marjorie L McCullough; Sabrina Paganoni; Kerry A Pierce; Michael A Schwarzschild; Aladdin H Shadyab; Jean Wactawski-Wende; Dong D Wang; Ying Wang; JoAnn E Manson; Alberto Ascherio Journal: Neurology Date: 2019-03-29 Impact factor: 9.910
Authors: Katharine Nicholson; James Chan; Eric A Macklin; Mark Levine-Weinberg; Christopher Breen; Rachit Bakshi; Daniela L Grasso; Anne-Marie Wills; Samad Jahandideh; Albert A Taylor; Danielle Beaulieu; David L Ennist; Ovidiu Andronesi; Eva-Maria Ratai; Michael A Schwarzschild; Merit Cudkowicz; Sabrina Paganoni Journal: Ann Clin Transl Neurol Date: 2018-10-22 Impact factor: 4.511
Authors: Nick S Verber; Stephanie R Shepheard; Matilde Sassani; Harry E McDonough; Sophie A Moore; James J P Alix; Iain D Wilkinson; Tom M Jenkins; Pamela J Shaw Journal: Front Neurol Date: 2019-04-03 Impact factor: 4.003
Authors: Ovidiu C Andronesi; Katharine Nicholson; Kourosh Jafari-Khouzani; Wolfgang Bogner; Jing Wang; James Chan; Eric A Macklin; Mark Levine-Weinberg; Christopher Breen; Michael A Schwarzschild; Merit Cudkowicz; Bruce R Rosen; Sabrina Paganoni; Eva-Maria Ratai Journal: Front Neurol Date: 2020-12-03 Impact factor: 4.003
Authors: Margarita Gerou; Benjamin Hall; Ryan Woof; Jessica Allsop; Stephen J Kolb; Kathrin Meyer; Pamela J Shaw; Scott P Allen Journal: Neurobiol Aging Date: 2021-04-27 Impact factor: 4.673